Whether facing a pipeline setback, managing asset transactions, or replacing sunsetting product revenues, most companies will eventually need to adapt their pipeline strategies. Today, Ovid’s President and COO, Meg Alexander, is presenting at the 2024 Fierce Biotech Summit to share key learnings from Ovid and other companies that have successfully navigated the challenges of pivoting and rebuilding a company’s pipeline. Say hi if you are at the event: https://lnkd.in/gZiJ8nHE
Ovid Therapeutics的动态
最相关的动态
-
In the latest episode of Exceptional Leaders / Exceptional Ideas, our CEO Tim Van Hauwermeiren discusses his entrepreneurial journey, navigating the?launch of argenx, and our approach to developing innovative treatments for autoimmune conditions. Watch the full episode below.?
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
Asset assessment for in licensing and out licensing, R&D, US FDA IND Regulatory Submission for BTD/ODD/AA, Global/local Clinical Studies, Board of Directors, International Speaker, CDP, M&A, Hiring, CME advice, Editor.
Not easy to start a new company
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
Inspiring Science, Inspiring Teamwork, Inspiring Entrepreneurship @argenx . See below for the full interview with our CEO Tim Vanhauwermeiren.
“We had no money, we had no business plan.” Tim Van Hauwermeiren, CEO of argenx, reflects on how he and his co-founders beat the odds when they launched the biotech in 2008. https://mgstn.ly/3wRCHS7
-
AAX Biotech Secures Funding to Drive Technology Development and Expansion ?? We are excited to announce that AAX Biotech AB has successfully raised 7 MSEK in a funding round backed by both new and existing investors. The capital will be used to support our ongoing growth and innovation efforts, strengthening our internal capabilities and expanding our project portfolio. The funding round included a rights issue offered to current shareholders, alongside a directed share issue aimed at new investors such as Life Science Invest (LSI Epsilon). Several existing shareholders, including Karolinska Institutet Holding, Northislet, Hjalmar Didrikson through HJKK Didrikson AB and Phase2Phase Biopharma Ventures, additionally chose to increase their stake in AAX Biotech. With these resources, we are positioned to deliver innovative solutions that address some of the most critical medical challenges. Full story: https://lnkd.in/dcSBZ5Mm #AAX #Biotech #AntibodyTherapeutics #NextGenTherapeutics #DrugDevelopment
-
-
Today's headline from Fierce Biotech was an article from James Waldron titled "Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs." Nice to see the #IPO market opening for biotech and that public markets apetitite for biotech remains alive and well. https://lnkd.in/eDHwgq7x For the year, public investment in biotech is trending towards the third highest total on record. (Data on public investment to date from BioCentury Inc.) Center for Integration of Science and Industry at Bentley University
-
-
Optimising operations will help biotechs facilitate movement through critical milestones, avoid delays and help navigate this most difficult program phase. Learn how biotech sponsors can mitigate costly, time-consuming changes by simplifying protocol design in part two of our biotech funding whitepaper series. https://ow.ly/ZyUc50RrXHn
-
-
Today we added 60-plus assets across 30 partners to the XOMA Royalty portfolio. Our strategic transaction with Twist Bioscience provides XOMA Royalty with a 50% economic interest in the royalties and milestones originating from Twist Biopharma Solutions.? With 6 commercial assets and 7 in Phase 3 development today, we have been working to build and scale XOMA Royalty’s future commercial asset portfolio. Brad Sitko stated, “This transaction reinforces our commitment to a disciplined capital deployment strategy and showcases our ability to create bespoke royalty capital solutions to meet the unique needs of our partners.” ?XOMA Royalty’s portfolio now has over 100 assets with milestone potential over $1 billion. You can read our press release here https://bit.ly/3BUXsPl ? #Royalty #Royalties #Monetization #Milestones #Strategy #Aquisition #Portfolio #Growth #Scale #RoyaltyCapitalSolutions
-
-
Shedding the "dirty word" connotation: I wrote about the appetite for biotech crossover rounds this morning for Endpoints News, just as two of the drug development industry's largest private financings of 2024 were announced (Alumis' $259 million and Sionna's $182 million). #crossover #biotech #drugdevelopment #lifesciencesindustry #biotechindustry #pharma #venturecapital #publicmarkets #ipo
-
?? ?? Biotech investors and corporate development professionals We've just launched Gosset, the platform that provides insights about biotech assets. Try our demo here: https://lnkd.in/gK2mUiTm and comment on this post to get early access to the full version (or just to help us spread the word:)
-
Don’t miss out on our dedicated track for Strategy and Dealmaking at the Fierce Biotech Summit on Sept 30th – Oct 1st. ??Click here to learn more https://ow.ly/BWJR50SzHck Explore the dynamics of partnerships, collaborations, and investments in biotech. Examine the changing landscape of deal structures, innovative licensing models, and successful case studies of strategic alliances. Stay updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FiercePharma #BiotechPR #BiotechEvents
-
